Replimune stock.

Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.At Replimune, we are developing an emerging class of cancer treatments called oncolytic immunotherapies.­ Oncolytic immunotherapy has the potential to treat patients with a variety of tumor types and improve on existing immunotherapies. Our goal is to revolutionize cancer treatment by making personalized therapy a practical reality for all ...Jan 4, 2023 · The inducement awards consist of a non-qualified stock option to purchase 82,500 shares of the Company’s common stock and restricted stock units representing 55,000 shares of the Company’s common stock. The option has an exercise of $27.20 per share, which is equal to the closing price of the Company’s common stock on the date of grant ... Replimune will supply Incyte with RP1 for the study and share costs. ... Research and development expenses included $3.3 million in stock-based compensation expenses for the first quarter ended ...Rocket Pharmaceuticals, Inc. 22.82. +0.57. +2.54%. In this article, we will take a look at the 12 stocks with biggest upside potential according to analysts. To skip our analysis of recent market ...

Replimune Group Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-3.531 per share for the current fiscal year. Replimune Group Inc does not currently pay a dividend.

Replimune Group's results for treatment of patients with cutaneous squamous cell carcinoma are expected in Q4 2023. Click here to read our take on REPL stock.

In conclusion, Replimune Group Inc’s stock performance has been buoyed by positive price forecasts from 10 analysts, with a median target price of $50.00. Despite reporting negative earnings per share for the current quarter, investors remain optimistic about the company’s long-term potential.Replimune will supply Incyte with RP1 for the study and share costs. ... Research and development expenses included $3.3 million in stock-based compensation expenses for the first quarter ended ...10.39 +0.10 (0.97%) At close: Nov 24, 2023, 1:00 PM 10.86 +0.46 (4.48%) After-hours: Nov 24, 2023, 1:26 PM EST Financials No 1Y chart data available About …Nov 18, 2023 · Christopher has made over 1 trades of the Replimune Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Christopher sold 5,255 units of REPL stock worth $57,385 on 16 November 2023. The largest trade Christopher's ever made was selling 5,255 units of Replimune Inc stock on 16 November 2023 worth over $57,385. The inducement awards consist of a non-qualified stock option to purchase 82,500 shares of the Company’s common stock and restricted stock units representing 55,000 shares of the Company’s common stock. The option has an exercise of $27.20 per share, which is equal to the closing price of the Company’s common stock on the date of grant ...

Dec 9, 2022 · In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 4,200,000 shares of its common stock at a purchase price of $23.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share ...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...

Customizable interactive chart for Replimune Group Inc with latest real-time price quote, charts, latest news, technical analysis and opinions.Dec 1, 2023 · Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively ... Replimune Group Stock Forecast · Over the next 52 weeks, Replimune Group has on average historically risen by 19.6% based on the past 5 years of stock ...See Insiders’ Hot Stocks on TipRanks >> Replimune Group (REPL) Barclays analyst Peter Lawson assigned a Buy rating to Replimune Group yesterday and set a price target of $50.00.The company’s ...Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 11.71 +0.53 (+4.74%) At close: 04:00PM EST 11.71 0.00 (0.00%) After hours: 04:20PM EST 1d 5d 1m...15 Okt 2020 ... Replimune stock rallied on leaked RP1 and RP2 clinical trial data. Its cash position enables it to invest more in clinical studies.Nov 21, 2023 · HC Wainwright dropped their price target on shares of Replimune Group from $50.00 to $48.00 and set a “buy” rating on the stock in a research report on Monday, November 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Replimune Group has a consensus rating of “Buy” and an average price ...

A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock.6.68. +0.68. +11.33%. Get Replimune Group Inc (REPL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.To begin my analysis, Replimune's Q2 earnings revealed an upswing in expenditures, with R&D costs climbing 37% to $40.4M and SG&A expenses up 33% to $15.2M, culminating in a heightened operating ...Track Replimune Group Inc (REPL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsReplimune Group, Inc. Common Stock (REPL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.REPL Price Action: Shares of Replimune Group fell 2.4% to close at $15.65 on Wednesday. Read More: Delta Air Lines, Harley-Davidson And 3 Stocks To Watch Heading Into Thursday SHARE THIS POST

PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …During the last session, Replimune Group Inc (NASDAQ:REPL)’s traded shares were 0.83 million, with the beta value of the company hitting 1.46. At the end of the trading day, the stock’s price was $11.71, reflecting an intraday gain of 4.74% or $0.53. The 52-week high for the REPL share is $29.52, that puts it down -152.09 from that peak ...

WOBURN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced a clinical development update for CERPASS, its registration-directed global randomized Phase 2 clinical trial of RP1 in combination with …Replimune story: Exercise or conversion by Pamela Esposito of 25800 shares of Replimune subject to Rule 16b 3 and other headlines for Replimune GroupAccording to the issued ratings of 6 analysts in the last year, the consensus rating for Replimune Group stock is Buy based on the current 6 buy ratings for REPL. The average twelve-month price prediction for Replimune Group is $51.33 with a high price target of $70.00 and a low price target of $34.00. Learn more on REPL's analyst rating …1,703.30 -8.20(-0.48%) Crude Oil 76.65 -0.52(-0.67%) Gold 1,943.70 +6.00(+0.31%) Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. …Replimune remains on track to initiate its Phase 2 development program with RP2/3 in the first half of 2023. As previously announced, this program is intended to include Phase 2 clinical trials in ...A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Find the latest Replimune Group, Inc. (REPL) stock analysis from Seeking Alpha's top analysts: exclusive research and insights from bulls and bears.

The shares of common stock and the pre-funded warrants described above are being offered by Replimune pursuant to its shelf registration statement on Form S-3, including a base prospectus, that ...

About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell …Track Replimune Group Inc (REPL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsToday's High Today's Low 52 Week High 52 Week Low FL Technical Analysis Tools & Settings Open High Low Close Volume Volume remove 1DY | 5DY | | 3M | | YTD | | | | Max |Replimune | 9,469 followers on LinkedIn. Replimune's mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response.Shares of Replimune Group Inc. (REPL) surged more than 46% to touch a new high of $46.28 in intraday trading on Wednesday after an analyst at Roth Capital Tony Butler hiked his price target on the ...According to the issued ratings of 6 analysts in the last year, the consensus rating for Replimune Group stock is Buy based on the current 6 buy ratings for REPL. The average twelve-month price prediction for Replimune Group is $51.33 with a high price target of $70.00 and a low price target of $34.00. Learn more on REPL's analyst rating …PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …See Replimune Group, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. ... Based on 10 analysts giving stock ratings to REPL in the past 3 months. EPS. …

A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Nov 8, 2023 · WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated data from a cohort of metastatic uveal melanoma patients enrolled in the open-label, multicenter, Phase 1 study of RP2 as a single agent and in combination with nivolumab. Dec 2, 2023 · Replimune Group Inc (REPL) registered a 4.74% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.74% in intraday trading to $11.71 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is 12.70%, and it has moved by -18.05% in 30 days. Replimune Group Enters Oversold Territory (REPL) Dividend Channel - Fri Feb 11, 4:10PM CST . Legendary investor Warren Buffett advises to be fearful when others are greedy, …Instagram:https://instagram. how to invest in xmgc etfbest penny stocks to buy tomorrownasdaq amli Replimune Group Inc [REPL] stock prices are up 4.74% to $11.71 at the moment. An important factor to consider is whether the stock is rising or falling in short … homegoods vs bed bath and beyondpstg stock price Replimune Group Inc. is doing cutting-edge work in the field of new cures for cancer. They are "pioneering a novel class of tumor-directed oncolytic immunotherapies (TDOI) designed to kill the ...Stock USD 19.28 0.44 2.23% Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding Replimune Group is 'Hold' forex trader app 10.39 +0.10 (0.97%) At close: Nov 24, 2023, 1:00 PM 10.86 +0.46 (4.48%) After-hours: Nov 24, 2023, 1:26 PM EST Financials No 1Y chart data available About …Founded Date Mar 2015. Founders Philip Sparke, Robert Coffin. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Replimune Group Inc. Stock Symbol NASDAQ:REPL. Company Type For Profit. Contact Email [email protected]. Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the …Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.